Minimal change disease and COVID-19 vaccination: Four cases and review of literature.

Clinical Nephrology. Case Studies Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI:10.5414/CNCS110924
Preeti Chandra, Marisa Roldao, Cinthia Drachenberg, Paulo Santos, Naoki Washida, Alexander Clark, Bipin Bista, Ryunosuke Mitsuna, Angelito Yango
{"title":"Minimal change disease and COVID-19 vaccination: Four cases and review of literature.","authors":"Preeti Chandra,&nbsp;Marisa Roldao,&nbsp;Cinthia Drachenberg,&nbsp;Paulo Santos,&nbsp;Naoki Washida,&nbsp;Alexander Clark,&nbsp;Bipin Bista,&nbsp;Ryunosuke Mitsuna,&nbsp;Angelito Yango","doi":"10.5414/CNCS110924","DOIUrl":null,"url":null,"abstract":"<p><p>There have been multiple reports of the development of de novo or relapse of glomerular diseases after SARS-CoV-2 vaccination. While most of them have occurred with the mRNA vaccines (Pfizer/BioNTech and Moderna/NIAID), there also have been reports associated with the vector vaccines (AstraZeneca/ChAdOx1-S) vaccine and the inactivated vaccines. Minimal change disease (MCD) is one of the more common glomerular diseases noted to have been associated with the COVID-19 vaccination. We report here 4 more cases of MCD occurring in association with the COVID-19 vaccine, 3 were de novo cases, and 1 case had a relapse of MCD. We also review all the 41 cases described thus far in the literature and review potential common pathways activated by the vaccination that play a role in the pathogenesis of MCD.</p>","PeriodicalId":10398,"journal":{"name":"Clinical Nephrology. Case Studies","volume":" ","pages":"54-63"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316439/pdf/","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nephrology. Case Studies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/CNCS110924","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

There have been multiple reports of the development of de novo or relapse of glomerular diseases after SARS-CoV-2 vaccination. While most of them have occurred with the mRNA vaccines (Pfizer/BioNTech and Moderna/NIAID), there also have been reports associated with the vector vaccines (AstraZeneca/ChAdOx1-S) vaccine and the inactivated vaccines. Minimal change disease (MCD) is one of the more common glomerular diseases noted to have been associated with the COVID-19 vaccination. We report here 4 more cases of MCD occurring in association with the COVID-19 vaccine, 3 were de novo cases, and 1 case had a relapse of MCD. We also review all the 41 cases described thus far in the literature and review potential common pathways activated by the vaccination that play a role in the pathogenesis of MCD.

微小变化病与COVID-19疫苗接种:4例及文献综述。
已有多例关于接种SARS-CoV-2后肾小球疾病重新发病或复发的报道。虽然大多数病例发生在mRNA疫苗(辉瑞/BioNTech和Moderna/NIAID)上,但也有与载体疫苗(阿斯利康/ChAdOx1-S)疫苗和灭活疫苗相关的报道。微小变化病(MCD)是与COVID-19疫苗接种相关的较常见肾小球疾病之一。我们在此报告了另外4例与COVID-19疫苗相关的MCD, 3例为新发病例,1例为MCD复发。我们还回顾了迄今为止在文献中描述的所有41例病例,并回顾了在MCD发病机制中发挥作用的疫苗激活的潜在共同途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信